Zoetis (NYSE:ZTS) Hits New 12-Month Low - Time to Sell?

Key Points

• Zoetis (NYSE: ZTS) hit a new 12-month low at $139.56 during trading, with trading volume reaching 677,042 shares.
• Wall Street analysts have recently downgraded Zoetis, with Stifel Nicolaus and Leerink Partners decreasing their target prices significantly, while Piper Sandler maintained an 'overweight' rating but raised its target.
• Despite the drop in stock price, Zoetis reported strong financial results for its last quarter, exceeding EPS and revenue estimates, suggesting resilience in its performance.

Zoetis Inc. (NYSE:ZTS - Get Free Report)'s stock price reached a new 52-week low during trading on Thursday . The company traded as low as $139.56 and last traded at $139.72, with a volume of 677042 shares traded. The stock had previously closed at $141.67.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research analyst reports. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Argus restated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Zoetis currently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Stock Performance

The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a fifty day moving average price of $150.63 and a two-hundred day moving average price of $156.07. The stock has a market capitalization of $62.12 billion, a PE ratio of 24.12, a P/E/G ratio of 2.29 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the prior year, the business posted $1.56 earnings per share. The company's revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ZTS. Lindbrook Capital LLC raised its holdings in shares of Zoetis by 1.8% in the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock worth $612,000 after buying an additional 65 shares in the last quarter. Scott & Selber Inc. increased its holdings in Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company's stock valued at $1,817,000 after purchasing an additional 67 shares in the last quarter. North Star Asset Management Inc. increased its holdings in Zoetis by 4.9% during the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company's stock valued at $225,000 after purchasing an additional 67 shares in the last quarter. Secure Asset Management LLC increased its stake in shares of Zoetis by 2.9% in the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company's stock valued at $382,000 after buying an additional 68 shares during the period. Finally, Quotient Wealth Partners LLC increased its stake in shares of Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after buying an additional 72 shares during the period. Institutional investors own 92.80% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.